Ovarian Cancer-Pipeline Insights, 2016

  • ID: 3774308
  • Drug Pipelines
  • 260 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Baxter Oncology
  • Medison Pharma
  • Merck KGaA
  • Merck KGaA
  • Novartis Pharmaceuticals
  • MORE
“Ovarian Cancer -Pipeline Insights, 2016” provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Ovarian Cancer. Ovarian cancer is the sudden growth of the cells in the ovary and is a type of cancer that affects females only. The cancer forms in tissues of the ovary when normal cells are affected. It can affect either one or both the ovaries.

It is estimated that every year approximately 21,000 women in USA and 5,500 women in UK are diagnosed with ovarian cancer. It is the eighth most common cancer among women in USA and fifth most common cancer among females in UK. The report provides the in-depth analysis of the pipeline assets across the Ovarian Cancer. The Report gives insights on 225+ products. It also includes around 185+ companies which are active in this field. Ovarian Cancer -Pipeline Insights, 2016 Report covers the pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases.

The Report also provides Ovarian Cancer related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Ovarian Cancer. These days’ companies are focusing on the Targeted Therapy for cancer. Roche’s Pertuzumab, Merck Avelumab and Morphotek’s Farletuzumab is the monoclonal antibody in Phase III stage competing against the other small molecules in development. Many big pharmaceuticals companies are involved in ovarian cancer with their preregistration products. Cediranib of AstraZeneca and Paclitaxel of Oasmia Pharmaceutical AB is ready to hit the market in few coming years. These are in preregistration stage of development.

Note: This report will be delivered to the client in 48 hours

Report Highlights:
- The new report, provides a Ovarian Cancer Landscape across the globe
- The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
- Coverage of the Ovarian Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Ovarian Cancer and also provide company profiling
- Pipeline products coverage based on various stages of development from NDA filings to discovery.
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Baxter Oncology
  • Medison Pharma
  • Merck KGaA
  • Merck KGaA
  • Novartis Pharmaceuticals
  • MORE
Table of Contents

- Ovarian Cancer Overview
- Signs and symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Therapeutics under Development by Companies
- Last Stage Products (Phase III)
- Comparative Analysis
- Mid Stage Products (Phase II)
- Comparative Analysis
- Early Stage Products (Phase I and IND)
- Comparative Analysis
- Discovery and Pre-clinical stage Products
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Dormant Products
- Comparative Analysis
- Discontinued Products
- Comparative Analysis
- Appendix
- Methodology
- Consulting Services
- About us
- Contact Us
- Disclaimer

List of Tables

- 1:Number of Products Under Development for Ovarian cancer, 2016
- Table 2: Number of Products under Development by Companies, 2016
- Table 3: Last Stage Products (Phase III and Filed),2016
- Table 4: Mid Stage Products (Phase II), 2016
- Table 5: Early Stage Products (Phase I), 2016
- Table 6: Pre-Clinical and Discovery Products, 2016
- Table 7: Assessment by Monotherapy Products, 2016
- Table 8: Assessment by Combination Products, 2016
- Table 9:Assessment by Route Of Administration, 2016
- Table 10:Assessment by Stage and Route Of Administration, 2016
- Table 11:Assessment by Molecule Type, 2016
- Table 12:Assessment by Stage and Molecule Type, 2016
- Table 13: Dormant Products, 2016
- Table 14:Discontinued Products, 2016

List of Figures
- Figure 1: Number of Products under Development for Ovarian cancer, 2016
- Figure 2:Last Stage Products (Phase III), 2016
- Figure 3: Mid Stage Products (Phase II), 2016
- Figure 4:Early Stage Products (Phase III), 2016
- Figure 5: Discovery and Pre-clinical Stage Products, 2016
- Figure 6: Assessment by Monotherapy Products, 2016
- Figure 7: Assessment by Combination Products, 2016
- Figure 8: Assessment by Route of Administration, 2016
- Figure 9: Assessment by Stage and Route of Administration, 2016
- Figure 10: Assessment by Molecule Type, 2016
- Figure 11:Assessment by Stage and Molecule Type, 2016
- Figure 12:Dormant Products, 2016
- Figure 13:Discontinued Products, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- AbbVie Inc.
- Oasmia Pharmaceutical AB
- Merck KGaA
- Novartis Pharmaceuticals
- Baxter Oncology
- Medison Pharma
- Orion Pharmaceuticals
- Merck KGaA
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll